RBC Capital Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $126
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has initiated coverage on Axsome Therapeutics (NASDAQ:AXSM) with an Outperform rating and set a price target of $126.
January 25, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Leonid Timashev initiated coverage on Axsome Therapeutics with an Outperform rating and a price target of $126, which could positively influence the stock's performance.
Analyst ratings, especially from reputable firms like RBC Capital, can significantly influence investor sentiment and stock prices. An Outperform rating suggests that the analyst believes AXSM will perform better than the market or its sector, which can attract investors. The price target of $126 is a strong bullish signal, indicating a substantial upside from the current trading price. This can lead to increased investor interest and potentially drive up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100